Emcure Pharma Q2 Results: Stock jumps 7% after international expansion, domestic momentum drives growth
Emcure Pharma is confident of the domestic business growth to continue for the full year as the team is strengthened and portfolio also gains traction. As part of the "One Emcure" vision, Zuventus and Emcutix will be merged with the holding company.